Ποια είναι η τιμή για Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Η τιμή για Jacobio Pharmaceuticals Group Co., Ltd. (1167) είναι $0.84111496

Ποια είναι η κεφαλαιοποίηση αγοράς για Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Η κεφαλαιοποίηση αγοράς για Jacobio Pharmaceuticals Group Co., Ltd. (1167) είναι $657.90M

Jacobio Pharmaceuticals Group Co., Ltd. (1167) Τιμή και Κεφαλαιοποίηση Αγοράς

Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.

Η τιμή για 1167	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$6,729.76 $657.90M	NVDA	$5.264T	+799,999.32%
$6,010.49 $657.90M	AAPL	$4.701T	+714,486.28%
$5,340.44 $657.90M	GOOG	$4.177T	+634,824.21%
$4,880.47 $657.90M	MSFT	$3.817T	+580,138.75%
$3,664.56 $657.90M	AMZN	$2.866T	+435,578.53%

Η τιμή για 1167

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$6,729.76 $657.90M